Tanabe Pharma announces EU marketing authorization for Onerji®
Onerji® treats motor fluctuations in advanced Parkinson's disease via continuous subcutaneous infusion. Phase 3 trials showed increased ON time and reduced OFF time.
Latest Tanabe Pharma News & Updates
See the latest news and media coverage for Tanabe Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Last updated
Latest news about Tanabe Pharma
In short: Tanabe Pharma underwent a major rebranding following its acquisition by Bain Capital and sold its global ALS business to Shionogi for $2.5 billion.
Company announcements
Tanabe Pharma receives GHIT Fund grant for anti-malarial drugs
The JPY 700 million grant supports two-year preclinical development with MMV and UGA for next-generation drugs effective against falciparum and vivax malaria.
Tanabe Pharma completes edaravone business transfer to Shionogi
The transfer includes IP and sales rights for RADICAVA/Radicut in Japan, US, Canada, and others sequentially. It strengthens Tanabe's financial foundation for pipeline investments.
Tanabe Pharma dissolves BIKEN Co. joint venture
BIKEN Foundation acquires Tanabe Pharma's shares on April 1, 2026, making BIKEN its wholly owned subsidiary. They continue as manufacturer and distributor.
Media coverage
Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing
Detailed price information for Mineralys Therapeutics Inc (MLYS-Q) from The Globe and Mail including charting and trades.
Tanabe Pharma America Announces Finalization of RADICAVA (edaravone) Transfer to Shionogi
Tanabe Pharma America, Inc. (TPA), the wholly owned subsidiary of Tanabe Pharma Corporation, today announced the finalization of the transfer of the RADICAVA (edaravone) business...
Tanabe readying new dersimelagon data for FDA filing
Japan’s Tanabe Pharma Corporation has announced detailed results from the Phase III INSPIRE study of investigational oral dersimelagon in people living with erythropoietic protoporphyria (EPP...
Exclusive: Tanabe’s Phase 3 win for drug targeting rare diseases that cause pain upon light exposure
Tanabe Pharma's dersimelagon shows positive Phase 3 results for EPP/XLP patients, extending sunlight exposure time before symptom onset compared to placebo at AAD meeting.
Never miss news about Tanabe Pharma
Track Tanabe Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Trending companies
Discover what's making headlines across other trending companies.
Fujitsu
Kennedy Wilson
CervoMed
Eoptolink
Ligent
InnoLight
Nauticus Robotics
Regentis Biomaterials
Clearfield
IMC
Helical Fusion
BDO
PwC
Icertis
Deloitte
Execo
Grant Thornton
Aktis Oncology
GEODNET
Moxie
Onorato
Aloe Care
Tombot
CarePredict
Labrador
Joy for All
Intuition Robotics
temi
Rocket55
Kreativ HQ
NATIV3
Snap Agency
The Guerrilla
ArcStone
Hook